Does a laboratory’s responsibility for corrective action listed on a FDA-483 begin at the conclusion of an inspection or upon receipt of correspondence from the originating bureau in which corrective action is requested?
The FDA-483 lists observations of violative conditions that have the capability to adversely
affect nonclinical laboratory studies. Corrective actions should be instituted as soon as
possible.
